Dasatanib has been used extensively as a second-line therapy in patients with chronic myelogenous leukemia with the BCR-ABL fusion protein, but, along with other c-Src-targeting TKIs, has produced generally disappointing results in solid malignancy clinical trials [68]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.